The aim of this study was to evaluate the efficiency and safety of simultaneous islet-kidney transplantation in patients of type 1 diabetes with end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Islet transplantation can result in insulin independence with excellent metabolic control when glucocorticoid-free immunosuppression is combined with the infusion of an adequate islet mass. Alemtuzumab (Campath-1H ®) is a 150-kDa humanized IgG1 monoclonal antibody that targets the CD52 antigen. Prolonged lymphocyte depletion can be expected following alemtuzumab treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
Fuzhou General Hospital
Fuzhou, Fujian, China
Exogenous insulin requirement
Time frame: 5
kidney function
Time frame: 5
Hemoglobin A1c
Time frame: 5
Glucose and C-peptide levels
Time frame: 5
Portal vein Ultrasound
Time frame: 1
liver function
Time frame: 5
Complete Blood Count
Time frame: 5
autoantibodies
Time frame: 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.